Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein
Brian T. Grimberg,Rachanee Udomsangpetch,Jia Xainli,Amy M. McHenry,Tasanee Panichakul,Jetsumon Sattabongkot,Liwang Cui,Moses J. Bockarie,Chetan E. Chitnis,John H. Adams,Peter A. Zimmerman,Christopher L. King,Christopher L. King +12 more
Reads0
Chats0
TLDR
These results show, for what is believed to be the first time, that both rabbit and human antibodies directed against PvDBPII reduce invasion efficiency of wild P. vivax isolated from infected patients, and suggest that a Pv DBP-based vaccine may reduce human blood-stage P.vivax infection.Abstract:
Background
Plasmodium vivax invasion requires interaction between the human Duffy antigen on the surface of erythrocytes and the P. vivax Duffy binding protein (PvDBP) expressed by the parasite. Given that Duffy-negative individuals are resistant and that Duffy-negative heterozygotes show reduced susceptibility to blood-stage infection, we hypothesized that antibodies directed against region two of P. vivax Duffy binding protein (PvDBPII) would inhibit P. vivax invasion of human erythrocytes.read more
Citations
More filters
Journal ArticleDOI
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
James G. Beeson,James G. Beeson,James G. Beeson,Damien R. Drew,Michelle J. Boyle,Gaoqian Feng,Freya J. I. Fowkes,Freya J. I. Fowkes,Freya J. I. Fowkes,Jack S. Richards,Jack S. Richards,Jack S. Richards +11 more
TL;DR: The current knowledge on this topic is reviewed, highlighting recent advances and research priorities, and several merozoite surface proteins show strong potential as malaria vaccines.
Journal Article
A research agenda for malaria eradication: vaccines.
Salim Abdulla,P. Agre,Pedro L. Alonso,Myriam Arévalo-Herrera,Quique Bassat,Fred Binka,Chetan E. Chitnis,Giampietro Corradin,Alan F. Cowman,J. Culpepper,H. del Portillo,Rhoel R. Dinglasan,Patrick E. Duffy,D. Gargallo,Brian Greenwood,Caterina Guinovart,B.F. Hall,Sócrates Herrera,Stephen L. Hoffman,A. Lanzavecchia,Odile Leroy,Myron M. Levine,Christian Loucq,Kamini Mendis,Jessica Milman,Vasee S. Moorthy,G. Pleuschke,Christopher V. Plowe,Steve Reed,Robert W. Sauerwein,Allan Saul,Louis Schofield,R.R. Sinden,J. Stubbs,T. Villafana,Dyann F. Wirth,Prashant Yadav,R. Ballou,Graham Brown,Ashley J. Birkett,W. Brandt,A. Brooks,Terrell Carter,A. Golden,C. Lee,J. Nunes,O. Puijalon,T. Raphael,H. Richards,C. Warren,C. Woods +50 more
TL;DR: The Malaria Eradication Research Agenda (malERA) Consultative Group on Vaccines present a research and development agenda to provide the tools to create vaccines that may be used during malaria eradication.
Journal ArticleDOI
The future for blood-stage vaccines against malaria.
Jack S. Richards,James G. Beeson +1 more
TL;DR: This review considers the evidence supporting the development of blood‐stage vaccines, the advantages and challenges of this approach, potential targets, human vaccine studies and future directions, and considers the challenges and priorities of overcoming antigenic diversity.
Journal ArticleDOI
Reduced Risk of Plasmodium vivax Malaria in Papua New Guinean Children with Southeast Asian Ovalocytosis in Two Cohorts and a Case-Control Study
Anna Rosanas-Urgell,Enmoore Lin,Laurens Manning,Patricia Rarau,Moses Laman,Nicolas Senn,Brian T. Grimberg,Livingstone Tavul,Danielle I. Stanisic,Leanne J. Robinson,John J. Aponte,Elijah Dabod,John C. Reeder,Peter Siba,Peter A. Zimmerman,Timothy M. E. Davis,Christopher L. King,Christopher L. King,Pascal Michon,Ivo Mueller +19 more
TL;DR: The association of Southeast Asian ovalocytosis with Plasmodium vivax infection by genotyping 1975 children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea and assessing P. v Vivax infection and disease in the children.
Journal ArticleDOI
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection
Christopher L. King,Pascal Michon,Ahmad Rushdi Shakri,Alexandra Marcotty,Danielle I. Stanisic,Peter A. Zimmerman,Jennifer L. Cole-Tobian,Ivo Mueller,Chetan E. Chitnis +8 more
TL;DR: A prospective cohort treatment/reinfection study of children residing in a P. vivax-endemic region of Papua New Guinea in which children were cleared of blood-stage infection and then examined biweekly for reinfection for 25 weeks finds that stable, high-level BIAbs displayed strain-transcending inhibition by reducing reinfectation with similar efficiency of PNG P.vivax strains characterized by six diverse PvDBPII haplotypes.
References
More filters
Journal ArticleDOI
The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy.
TL;DR: It is concluded that Duffy determinants (Fya or Fyb or both) on the erythrocyte surface are required for invasion of ery Throcytes by vivax merozoites.
Journal ArticleDOI
The neglected burden of Plasmodium vivax malaria
TL;DR: Feature of the transmission biology of P. vivax give this species greater resilience than the less robust Plasmodiumfalciparum in the face of conditions adverse to the transmission of the parasites, therefore, as control measures become more effective, the residual malaria burden is likely increasingly to become that of Pivax.
Journal ArticleDOI
Malaria Parasites and Other Haemosporidia
Journal ArticleDOI
Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry
Michael Farzan,Tajib Mirzabekov,Peter Kolchinsky,Richard T. Wyatt,Mark Cayabyab,Norma P. Gerard,Norma P. Gerard,Craig Gerard,Craig Gerard,Joseph Sodroski,Hyeryun Choe,Hyeryun Choe +11 more
TL;DR: The chemokine receptor CCR5, a principal HIV-1 coreceptor, is posttranslationally modified by O-linked glycosylation and by sulfation of its N-terminal tyrosines, a modification common to primate immunodeficiency virus coreceptors.